Clinical TrialID 6632
A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge
NCT01539473
Healthy Volunteers
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 6632
- Evidence Id
- 6632
- Core Evidence Id
- 6632
- Source Clinical Trial Id
- 6619
- Herb2 Clinical Trial Id
- HBCT006619
- Nct Id
- NCT01539473
- Title
- A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge
- Status
- Completed
- Phase
- Phase 1
- Study Result
- No
- Study Condition
- Healthy Volunteers
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose:
- Intervention
- DRUG: TR-701 FA with Tyramine|DRUG: Placebo-controlled withTyramine
- Intervention Allocation
- Randomized
- Intervention Model
- Single_Group
- Intervention Mask
- Double
- Intervention Purpose
- Gender
- All
- Age
- Adult
- Enrollment
- 30
- Outcome Measure
- Systolic Blood Pressure, To assess tyramine dose required to cause increase of 30 mmHg in systolic blood pressure, 14 days
- Sponsor Collaborator
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Funded By
- INDUSTRY
- Location
- Trius Investigator Site 001, Evansville, Indiana, 47710, United States
- Other Id
- 1986-032|TR701-105
- Start Date
- 2012-02
- Primary Completion Date
- 2012-05
- Completion Date
- 2012-05
- First Posted
- 2012-02-27
- Results First Posted
- Last Update Posted
- 2016-05-03
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT01539473
- Title Cn
- Title En
- A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge
- Bilingual Status
- semi_complete